MediWound Completes Enrollment Stage of its NexoBrid® Phase III Pediatric Study

MediWound Ltd completed the enrollment stage of its NexoBrid® Phase III pediatric clinical study. The completion of the study enrollment stage followed the FDA’s recent agreement to allow the NexoBrid® expanded access protocol to be expanded to include pediatric as well as adult burn patients.
[MediWound Ltd]
Press Release
Bookmark

No account yet? Register

0
Share

Syntrix Completes Initial SX-682 Dosing in Broad Phase I/II Cancer Trial Campaign Now Encompassing 5 Solid Cancer Types Plus Myelodysplastic Syndromes

Syntrix Pharmaceuticals announced it completed the initial SX-682 dosing in Phase I/II trials in myelodysplastic syndromes and metastatic melanoma.
[Syntrix Pharmaceuticals (PR Newswire Inc)]
Press Release
Bookmark

No account yet? Register

0
Share

Covera Health Enhances its Radiology Center of Excellence Program with Mammography AI for Breast Cancer Detection

Covera Health announced the integration of ScreenPoint Medical’s artificial intelligence tools into its quality analytics platform. Covera Health planned to leverage these tools to improve early detection of breast cancer for both patients and providers.
[Covera Health (Business Wire Inc)]
Press Release
Bookmark

No account yet? Register

0
Share

EdiGene Announces IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia Accepted for Review by China National Medical Products Administration

Inc. announced the Center for Drug Evaluation of China National Medical Products Administration has accepted for review the Company’s Investigational New Drug application for ET-01
https://www.edigene.com/media/49.htmlAbstract
Bookmark

No account yet? Register

0
Share

insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

insitro has entered into a five-year, discovery collaboration with Bristol Myers Squibb, focused on the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). They will apply their proprietary platform to create iPSC-derived disease models for ALS and FTD.
[insitro (Businesswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 To ImStem Biotechnology For Development Of Cell Therapy Candidate IMS001 For COVID-19 And Acute Respiratory Distress Syndrome

AgeX Therapeutics, Inc. and ImStem Biotechnology, Inc. announced that ImStem has obtained from AgeX a non-exclusive, royalty-bearing sublicense to use AgeX’s clinical-grade ESC line ESI-053 to derive ImStem’s investigational MSC product candidate IMS001 for development in COVID-19 as well as acute respiratory distress syndrome from other causes.
[AgeX Therapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

Accuray Announces Agreement with Brainlab to Expand CyberKnife® Platform Treatment Capabilities for the Neuro-Radiosurgery Market

Accuray, Inc. announced a collaboration with Brainlab, that will enhance and expand the Accuray CyberKnife® treatment platform for the neuro-radiosurgery market.The two companies partnered to provide the neuro-radiosurgery community with access to Brainlab Elements planning software, which will provide contouring capabilities optimized for neurosurgeons.
[Accuray, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis

Pfizer Inc. announced that the FDA accepted for filing and granted Priority Review designation to the company’s New Drug Application for abrocitini, an investigational oral once-daily Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in patients 12 and older.
[Pfizer Inc. (BusinessWire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Trans-Hit Biomarkers Announces Today a Partnership with Nexelis, Supporting Sample Procurement Activities for a Number of Strategic Projects Including COVID-19 Vaccines and Immuno-oncology Development Initiatives

Trans-Hit Biomarkers Inc. announced the signing of a partnership agreement with Laboratoires Nexelis Canada Inc. to support prophylactic and therapeutic vaccine development programs sponsored by global pharmaceutical companies, innovative biotechnology companies, and prestigious governmental and non-governmental organizations including Bill and Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations.
[Trans-Hit Biomarkers, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally.
[Apellis Pharmaceuticals, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Vaxil Enters Into a Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases (“USAMRIID”)

VAXIL BIO LTD. announced that it has entered into a cooperative research and development agreement with USAMRIID under which USAMRIID will test CorVax™ for its ability to specifically prevent COVID-19 in mice.
[VAXIL BIO LTD. (GlobeNewswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share
Share